Ultragenyx to Host Conference Call for Third Quarter 2025 Financial Results and Corporate Update
Ultragenyx (NASDAQ: RARE) will host a conference call at 5:00 p.m. ET on Tuesday, November 4, 2025 to discuss third quarter 2025 financial results and a corporate update for the period ended September 30, 2025.
The live webcast and replay will be available at https://ir.ultragenyx.com/events-presentations. The replay will remain available for three months.
Ultragenyx (NASDAQ: RARE) terrà una conference call alle ore 17:00 ET di martedì 4 novembre 2025 per discutere i risultati finanziari del terzo trimestre 2025 e un aggiornamento aziendale per il periodo chiuso al 30 settembre 2025.
La trasmissione in diretta e la replica saranno disponibili all'indirizzo https://ir.ultragenyx.com/events-presentations. La replica rimarrà disponibile per tre mesi.
Ultragenyx (NASDAQ: RARE) organizará una conferencia telefónica a las 5:00 p.m. ET del martes 4 de noviembre de 2025 para analizar los resultados financieros del tercer trimestre de 2025 y una actualización corporativa para el periodo terminado el 30 de septiembre de 2025.
La transmisión en vivo y la repetición estarán disponibles en https://ir.ultragenyx.com/events-presentations. La repetición estará disponible durante tres meses.
Ultragenyx(나스닥: RARE)는 2025년 11월 4일 화요일 오후 5시 ET에 제3분기 2025년 재무 실적 및 2025년 9월 30일 종료 기간에 대한 기업 업데이트를 논의하기 위한 컨퍼런스 콜을 개최합니다.
생방송 및 재방송은 https://ir.ultragenyx.com/events-presentations에서 이용 가능하며, 재방송은 3개월 동안 남아 있습니다.
Ultragenyx (NASDAQ : RARE) animera une conférence téléphonique à 17h00, heure de l'Est, le mardi 4 novembre 2025 pour discuter des résultats financiers du troisième trimestre 2025 et une mise à jour d'entreprise pour la période se terminant le 30 septembre 2025.
La diffusion en direct et la rediffusion seront disponibles sur https://ir.ultragenyx.com/events-presentations. La rediffusion restera disponible pendant trois mois.
Ultragenyx (NASDAQ: RARE) wird am Dienstag, dem 4. November 2025 um 17:00 Uhr ET eine Telefonkonferenz abhalten, um die Ergebnisse des dritten Quartals 2025 sowie ein Unternehmensupdate für den Zeitraum bis zum 30. September 2025 zu besprechen.
Der Live-Webcast und die Wiederholung stehen unter https://ir.ultragenyx.com/events-presentations zur Verfügung. Die Wiederholung wird drei Monate lang verfügbar sein.
Ultragenyx (NASDAQ: RARE) ستعقد مكالمة مؤتمر في الساعة 5:00 مساءً بتوقيت شرق الولايات المتحدة يوم الثلاثاء 4 نوفمبر 2025 لمناقشة نتائج الأعمال للربع الثالث من 2025 وتحديثًا للشركة للفترة المنتهية في 30 سبتمبر 2025.
سيكون البث المباشر وإعادة التشغيل متاحين على https://ir.ultragenyx.com/events-presentations، وستبقى إعادة التشغيل متاحة لمدة ثلاثة أشهر.
Ultragenyx (NASDAQ: RARE) 将于美东时间 2025年11月4日星期二下午5:00 举行电话会议，讨论 2025 年第三季度财务业绩及截至 2025年9月30日止期间 的公司更新。
现场直播和回放将可在 https://ir.ultragenyx.com/events-presentations 获取。回放将可用 三个月。
- None.
- None.
NOVATO, Calif., Oct. 28, 2025 (GLOBE NEWSWIRE) -- Ultragenyx Pharmaceutical Inc. (NASDAQ: RARE), a biopharmaceutical company focused on the development and commercialization of novel products for serious rare and ultra-rare genetic diseases, today announced that it will host a conference call at 5:00 p.m. ET on Tuesday, November 4, 2025, to discuss its financial results and corporate update for the quarter ending September 30, 2025.
The live and replayed webcast of the call will be available through the company’s website at https://ir.ultragenyx.com/events-presentations. The replay of the call will be available for three months.
About Ultragenyx Pharmaceutical Inc.
Ultragenyx is a biopharmaceutical company committed to bringing novel products to patients for the treatment of serious rare and ultra-rare genetic diseases. The company has built a diverse portfolio of approved therapies and product candidates aimed at addressing diseases with high unmet medical need and clear biology for treatment, for which there are typically no approved therapies treating the underlying disease.
The company is led by a management team experienced in the development and commercialization of rare disease therapeutics. Ultragenyx’s strategy is predicated upon time- and cost-efficient drug development, with the goal of delivering safe and effective therapies to patients with the utmost urgency.
For more information on Ultragenyx, please visit the company's website at: www.ultragenyx.com.
Contact Ultragenyx
Investors
Joshua Higa
ir@ultragenyx.com
Media
Jess Rowlands
media@ultragenyx.com
FAQ
When is Ultragenyx (RARE) scheduled to report Q3 2025 results?
How can investors listen to the Ultragenyx (RARE) Q3 2025 earnings call?
How long will the replay of Ultragenyx (RARE) Q3 2025 call be available?
What will Ultragenyx (RARE) discuss on the November 4, 2025 call?
Is the Ultragenyx (RARE) webcast free to access for the public?
